Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
|
|
- Helen Hines
- 7 years ago
- Views:
Transcription
1 Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital
2 Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens at relapse? New treatments
3 Myeloma Treatable but not curable After many years with little change several new drugs Survival improving Area of very active research clinical trials Initial treatment good information from trials current standard treatments Relapsed disease no standard but several options now
4 Treating myeloma is more than just anti-myeloma drugs Symptom control Supportive care Transfusions, EPO Treatment of infections etc General measures back care, hydration etc Pastoral / spiritual care
5 When to treat? Calcium increased Renal Impairment Anaemia Bone disease Hyperviscosity Spinal Cord compression
6 Emergency treatment Steroids Emergency radiotherapy Other treatments: antibiotics, transfusion, pain killers, bisphophonates + fluids, dialysis
7 Aim of Treatment Reduce myeloma activity Chemotherapy Strengthen bones Bisphosphonates Alleviate symptoms Improve quality of life Prevent further bone and organ damage
8 Treatment of bone disease BISPHOSPHONATES Sodium clodronate tablets Zeledronate intravenously Pamidronate intravenously Strengthen bones Stop myeloma driven bone breakdown Direct anti-myeloma effect
9 Kyphoplasty
10 Chemotherapy Chemotherapy Cancer
11 Myeloma treatment initial Divided into two groups: Younger patients (<70 years) who are candidates for autologous stem cell transplant Older patients, other patients not fit for autologous stem cell transplant
12 Younger patients The aim of standard initial treatment is to induce remission to spare stem cells (avoid melphalan at this stage) Then collect stem cells (peripheral blood) Then proceed to high dose melphalan (200mg/m 2 ) followed by blood stem cell rescue (autograft / autologous transplant)
13 Which chemotherapy in newly diagnosed myeloma? Myeloma IX Trial Eligible for Transplantation Not eligible for Transplantation Induction C-VAD or CTD MP or attenuated CTD Stem cell harvest Maximal response Consolidation Autologous transplantation Consider mini-allogeneic transplantation Maintenance No treatment or thalidomide
14 Induction chemotherapy High response rates Most regimens are given as an outpatient May require a tunnelled central line insertion Steroids important component & synergistic
15 Intravenous treatment : C-VAD Cyclophosphamide weekly orally day 1,8,15 Vincristine and Adriamycin intravenously via pump day 1-4 Dexamethasone (steroids) days 1-4 and Cycle repeated every 3 weeks 4-6 cycles Alternatives: VAD, C-VAMP, Z-DEX One cycle
16 Thalidomide: How it works
17 Thalidomide: Side effects Dose mg daily Side effects : drowsiness constipation peripheral neuropathy thrombosis
18 Oral treatments MPT Melphalan day 1-7 Prednisolone day 1-7 Thalidomide daily 1-28 Cycle repeated 4 weekly 6-9 courses CTD Cyclophosphamide weekly Thalidomide daily Dexamethasone in pulses Cycle repeated 3-4 weekly 4-9 courses
19 Which regimen for which patient? MPT Generally patients >70 Very well tolerated Not ideal in renal failure or if stem cell collection planned CTD (a) Generally patients <70 Patients in whom stem cell collection being considered Dexamethasone can give SEs
20 Treatment complications Gout Thrush Shingles Pneumonia
21 Treatment prophylaxis Drugs needed in addition to the chemotherapy to prevent side effects / complications: Anti-nausea drugs Antacids (omeprazole) Antivirals (aciclovir) Anti-gout drugs Antibiotics Antifungals (fluconazole) Laxatives Blood thinners (clexane)
22 Markers of disease activity Healthy plasma cells Antibodies Paraprotein (M-Protein) Myeloma plasma cells (cancer cells) Light chains (M-Protein) Serum free light chains SFLC Urinary BJP
23 Response to treatment
24 Treatment Jargon Paraprotein Complete response (CR) Partial response (PR) Abnormal antibody or protein made by myeloma cancer cells No abnormal protein (M-protein) detectable in blood or urine for > 6 Weeks < 5 % Plasma cells in bone marrow > 50 % reduction in blood M- protein and/or 90 % reduction in urine light chains Plateau No evidence of continuing myeloma- related organ damage Stable M-protein levels for > 3 months
25 Autologous stem cell transplant Used in selected younger patients (<70yrs) Used to consolidate the response and increase the duration of response Stem cells collected with chemo and GCSF High dose melphalan (HDM) used and the bone marrow rescued with patients own stem cells High risk chemotherapy with many side-effects. Mortality 1-3 %
26 How to replace the bone marrow autologous stem cell transplantation
27 Collect stem cells Chemo GCSF High-dose melphalan Stem cells returned Recovery Remission
28 Side-effects of stem cell transplant Mucositis Infection Bleeding Fluid retention Breathing difficulties
29 Maintenance treatment Thalidomide Figure 1. Event-free survival according to treatment arm Reference: Attal, M. et al. Blood 2006;108:
30 Treatment of relapsed myeloma If first remission lengthy (>1 year) consider same treatment again If not already had thalidomide consider thalidomide (with dexamethasone) Bortezomib (with dexamethasone) Bortezomib with liposomal doxorubicin Lenalidomide with dexamethasone Clinical trials Dexamethasone alone Supportive care
31 Not Suitable for transplant Treatment of relapse First Relapse Suitable for transplant Initial treatment with MPT or CTDa Initial treatment With VAD type regimen And HDT HDT not part of 1st line treatment and PBSC available > 6 months < 6 months < 12 months post autograft > months post Autograft. Retreat with MPT or CTDa CTD or velcade regimen CTD or Velcade 2 nd Autograft Autograft Second or later Relapse CTD velcade or C-weekly / dexa or lenalidomide or Other new agents
32 The Velcade three 29 th March 2007: The National Institute for Health and Clinical Excellence s (NICE) announced a review of its own ruling denying patients NHS access to Bortezomib (Velcade) Jacky Pickles, Janice Wrigglesworth and Marie Morton
33 Velcade : How it works
34 Side-effects of bortezomib Nausea Constipation Diarrhoea Low platelets Neuropathy
35 Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma (APEX study) Bortezomib, an inhibitor of proteasomes (sites of protein degradation in cells), has activity against advanced multiple myeloma This study compared bortezomib with highdose dexamethasone in relapsed myeloma Bortezomib was superior to dexamethasone in all end points and prolonged overall survival
36 Bortezomib (Velcade) Response in % as single agent Response 50 % if used with dexamethasone Licensed for relapsed and refractory disease Major toxicities are neuropathy, thrombocytopenia IV therapy 1.3 mg/m 2 days 1,4,8 and 11. Dexamethasone tablets days 1,2,4,5,8,9,11,12
37 Lenalidomide
38 Lenalidomide Strong data for 2 nd line use onwards Weber D et al Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. NEJM 2007;357:21 Dimopoulos M et al Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. NEJM 2007;357: patients in these trials Lena + Dexa vs Placebo + Dexa Patients who had progressed after >= 1 therapy 48 weeks Lena arm vs 20 weeks Dexa alone ORR 65%
39 Lenalidomide Related to thalidomide Oral medication taken D1 21 in a 28 day cycle Well tolerated Less sleepiness, constipation, neuropathy Clots Much more suppression of bone marrow (low white cells and platelets) fatigue
40 Future Risk stratified treatment Development of new targeted treatments New regimes using thalidomide, velcade and lenalidomide Development of other thalidomide analogs Continue to improve quality of life
41
Background Information Myeloma
Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationMULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationProtocol for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: MULTIPLE MYELOMA
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: MULTIPLE MYELOMA Patient information given at each stage following agreed information
More informationSTEM CELL TRANSPLANTS
UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the
More informationMULTIPLE MYELOMA Treatment Overview
MULTIPLE MYELOMA Treatment Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate
More informationIt can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better.
Patient information from the BMJ Group It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better. What is multiple
More informationMultiple. Powerful thinking advances the cure
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationUnderstanding Revlimid
Understanding Revlimid International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454 TheIMF@myeloma.org
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationA Science Writer s Guide to Multiple Myeloma
A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationAdvances in multiple myeloma
Oncology 295 Advances in multiple myeloma Multiple myeloma is a malignant disease characterised by a clonal population of plasma cells in the bone marrow. The disease occurs in the elderly and results
More informationPlasma cell dyscrasias Mark Drayson
Plasma cell dyscrasias Mark Drayson Mortality statistics for England and Wales. Deaths attributed to multiple myeloma from 1988-1997 by age cohort as a percentage of total (21,257) deaths Deaths in age
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationI've Just Been Diagnosed. with Multiple Myeloma, What s Next?
I've Just Been Diagnosed with Multiple Myeloma, What s Next? Table of Contents Message from a Survivor Introduction What is Multiple Myeloma? What Causes Multiple Myeloma? Genes & Multiple Myeloma What
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationMyeloma A Comprehensive Guide
Myeloma A Comprehensive Guide This guide is written for patients who have been diagnosed with myeloma. It will also be helpful for their families, carers and friends. It provides comprehensive information
More informationMyeloma. A guide for patients and families. 1800 620 420 leukaemia.org.au
Myeloma A guide for patients and families 1800 620 420 leukaemia.org.au Notes Contents Acknowledgments 4 Introduction 5 The Leukaemia Foundation 6 Blood cancers 10 What is myeloma? 16 Who gets myeloma?
More informationHenk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
DRTUMUMB, a CD38 Monoclonal ntibody Study in dvanced Multiple Myeloma an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-rm Phase I/II Study bstract #S576 Henk Lokhorst, Torben
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationREVLIMID and IMNOVID for Multiple Myeloma
REVLIMID and IMNOVID for Multiple Myeloma What is Multiple Myeloma? Multiple myeloma (MM) is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and immune suppression.
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationVAD Chemotherapy Regimen for Multiple Myeloma Information for Patients
VAD Chemotherapy Regimen for Multiple Myeloma Information for Patients The Regimen contains: V = vincristine (Oncovin ) A = Adriamycin (doxorubicin) D = Decadron (dexamethasone) How Is This Regimen Given?
More informationlenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited
Resubmission: lenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited 07 March 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationChapter 8. Summary, general discussion and future perspectives
Summary, general discussion and future perspectives 115 Summary Multiple Myeloma (MM) is characterized by a malignant proliferation of monoclonal plasma cells in the bone marrow, clinical presenting by
More informationAsymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells
ESSENTIALS Multiple Myeloma Diagnosed with Multiple Myeloma? It s important to understand everything you can about your diagnosis, possible treatments, and places to go for support and care. Cancer is
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35
Myeloma: diagnosis and management NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 NICE 2016. All rights reserved. Your responsibility The recommendations in this guideline represent
More informationWhat you need to know about. Multiple Myeloma. Based on a brochure from National Institutes of Health National Cancer Institute STDAVIDS.
What you need to know about Multiple Myeloma Based on a brochure from National Institutes of Health National Cancer Institute STDAVIDS.COM What you need to know about Multiple Myeloma Introduction...1
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationFEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES. Updated December, 2011. Authors: Nebu Koshy, MD. Binu Nair, MD. Gerhard Hildebrandt, MD
FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES Updated December, 2011 Authors: Nebu Koshy, MD Binu Nair, MD Gerhard Hildebrandt, MD Reinhold Munker, MD Glenn Mills, MD Mandatory initial tests
More informationMultiple. Powerful thinking advances the cure
Multiple Myeloma DISEASE OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
More informationInformation Pathway. Myeloma tests and investigations. Paraprotein measurement
Information Pathway Myeloma UK Broughton House 31 Dunedin Street Edinburgh EH7 4JG Tel: + 44 (0) 131 557 3332 Fax: + 44 (0) 131 557 9785 Myeloma Infoline 0800 980 3332 www.myeloma.org.uk Charity No. SC
More informationA Clinical Primer. for Managed Care Stakeholders
reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders
More informationMultiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.
Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help
More informationUnderstanding Multiple Myeloma. A guide for people with cancer, their families and friends.
Understanding Multiple Myeloma A guide for people with cancer, their families and friends. Understanding Multiple Myeloma A guide for people with cancer, their families and friends. First published 1998
More informationThe following investigations are required at diagnosis, so that a disease category and stage can be assigned (see below).
3 MULTIPLE MYELOMA Clinical features Multiple myeloma (MM) is a disease with a peak incidence in the 6 th and seventh decades of life, but can also occur in younger patients. It is characterised by infiltration
More informationHealth Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
More informationUnderstanding. Multiple Myeloma. Caring for people with cancer
Understanding Multiple Myeloma Caring for people with cancer Understanding Multiple myeloma This booklet has been written to help you understand more about multiple myeloma. It has been prepared and checked
More informationMULTIPLE MYELOMA. Overview
MULTIPLE MYELOMA Overview Steven R. Schuster, M.D. May 7, 2015 Objectives Give an overview of Multiple Myeloma Everything I know in 15 minutes Explain how genetic information can be used to personalize
More informationMyeloma. Ann Grace, myeloma survivor. This publication was supported in part by a grant from
Myeloma Ann Grace, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma
More informationPERIPHERAL STEM CELL TRANSPLANT INTRODUCTION
PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION This booklet was designed to help you and the important people in your life understand the treatment of high dose chemotherapy with stem cell support: a procedure
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationOutline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD
Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic
More informationTreatment of Myeloma Bone Disease
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
More informationMultiple Myeloma High-Dose Chemotherapy and Stem Cell Transplantation
Multiple Myeloma High-Dose Chemotherapy and Stem Cell Transplantation 1 About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF) was founded in 1998 by identical twin
More informationGlossary of Multiple Myeloma Terms
Some things that make multiple myeloma (MM) difficult to understand are the unfamiliar medical terms that some experts and healthcare providers use to explain it. You may come across words like these when
More informationLiving with multiple myeloma A guide for patients and caregivers
Living with multiple myeloma A guide for patients and caregivers VELCADE (bortezomib) is approved for the treatment of patients with multiple myeloma (a cancer of the plasma cells). Before you receive
More informationCleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program
Cleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program Our mission The primary mission is to provide patients and physicians access to innovative treatment options, medical expertise, and
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationUnderstanding Anemia and Fatigue
Understanding Anemia and Fatigue International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (USA & Canada) 818-487-7455 Fax: 818-487-7454 TheIMF@myeloma.org
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationThe Management of Myeloma & Plasma Cell Disorders
Kent & Medway - Cancer The Management of Myeloma & Plasma Cell Disorders Oncological Treatment Guidelines for the Management of Multiple Myeloma and other Plasma Cell Disorders & Pathway of Care Publication
More informationChapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E.
Chapter 2 Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses; a high incidence of oligoclonal serum immunoglobulins post transplantation S. Hovenga, J.Th.M. de Wolf, J.E.J.
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationMomentum in Multiple Myeloma Treatment
WHITE PAPER Momentum in Multiple Myeloma Treatment Dr. Harish P. Dave, MD, MBA Dr. Ben Manderman, MD Quintiles examines promising new approaches to more effective multiple myeloma treatments. HIGH RESPONSE
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationIntegrating novel agents into multiple myeloma treatment current status in Switzerland and treatment recommendations
current status in Switzerland and treatment recommendations Christian Taverna a, Mario Bargetzi b, Daniel Betticher c, Jürg Gmür d, Michael Gregor e, Dominik Heim f, Urs Hess g, Nicolas Ketterer h, Erika
More informationMultiple Myeloma Guidelines
Multiple Myeloma Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Dr. Neil Rabin, North Middlesex University Hospital NHST and UCLH Date of issue: 12.03.2015 Version
More informationcure A Patient s Guide Diagnosis Staging Treatment Options Side Effects and Complications Patient Stories Resources
A Patient s Guide tomultiple Myeloma Diagnosis Staging Treatment Options Side Effects and Complications Patient Stories Resources cure C ancer U pdates, R esearch & E ducation Combining science with humanity,
More informationGUIDELINES FOR THE MANAGEMENT OF MULTIPLE MYELOMA AND RELATED DISORDERS
GUIDELINES FOR THE MANAGEMENT OF MULTIPLE MYELOMA AND RELATED DISORDERS Dr Eleni Tholouli, Manchester Royal Infirmary Dr Jim Cavet, The Christie NHS Foundation Trust Version 3, Oct 2012-1 - .Table of contents..
More informationMyeloma. A guide for patients, families and whanau
Myeloma A guide for patients, families and whanau The Leukaemia & Blood Foundation is grateful to Janssen for sponsoring this booklet 1 CONTENTS PAGE Introduction 2 The Leukaemia & Blood Foundation 3 Bone
More informationTable of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help?
Table of Contents Accelerate Your Research 2 Introduction 3 I. From the Real World to the Lab 4 A. Diagnosing Multiple Myeloma 4 1. Lab Tests 4 2. Bone Marrow Exams 6 3. Imaging Studies 7 B. Subtypes of
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationMultiple Myeloma in HUSM. Dr Azlan Husin HUSM
Multiple Myeloma in HUSM Dr Azlan Husin HUSM Outline Overview Presenting features Progress in myeloma Global HUSM Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation
More informationInvestigation of B cell malignancies. Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital
Investigation of B cell malignancies Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital The B cell progression from «Pluripotent stem cell «Lymphoid committed stem cell «B lineage committed
More informationMyeloma pathways to diagnosis UCLP audit
Myeloma pathways to diagnosis UCLP audit Dr Neil Rabin Consultant Haematologist University College London Hospitals & North Middlesex University Hospital Myeloma Clinical Features Bone pain (70%) High
More informationMyeloma. Anne Grace, myeloma survivor. Support for this publication provided by
Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2015 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
More informationPersonalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease
/publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationMultiple Myeloma Understanding your diagnosis
Multiple Myeloma Understanding your diagnosis Multiple Myeloma Understanding your diagnosis When you first hear that you have cancer you may feel alone and afraid. You may be overwhelmed by the large amount
More informationDeep in the Bone. M a n a g i n g M u lt i p l e M y e l o m a
Deep in the Bone M a n a g i n g M u lt i p l e M y e l o m a b y Fa i t h R e i d e n b a c h It s smart, Lee Grayson says ruefully, describing the myeloma he s been fighting for eight years. It s an
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationMantle Cell Lymphoma and New Treatments on the Horizon
MANTLE CELL LYMPHOMA Mantle Cell Lymphoma and New Treatments on the Horizon Presented by James Armitage, MD University of Nebraska Medical Center Pierluigi Porcu, MD The Ohio State University Comprehensive
More informationm y f o u n d a t i o n i n f o s h e e t
Pain and Myeloma m y f o u n d a t i o n i n f o s h e e t Pain is the most common symptom of myeloma and can greatly affect all areas of your life, especially if it is untreated or poorly managed. This
More informationJanuary 23, 2008 State-of-the-Art Therapies for Multiple Myeloma William Bensinger M.D. Una Wilson Hosted By Andrew Schorr.
January 23, 2008 State-of-the-Art Therapies for Multiple Myeloma William Bensinger M.D. Una Wilson Hosted By Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the
More informationMYEL NEWL OMA Y DIA GNOSED
Information on NEWLY DIAGNOSED MYELOMA UAMS 1 ABOUT THE MYELOMA INSTITUTE The Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) is a leading center in the world for comprehensive
More informationMultiple Myeloma Patient Handbook. www.myeloma.ca
Multiple Myeloma Patient Handbook www.myeloma.ca Introduction This resource has been designed for: 1. Someone who has been newly diagnosed with myeloma and is wondering what it means and what the future
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationMultiple Myeloma. What is multiple myeloma? Low blood counts
Multiple Myeloma What is multiple myeloma? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationAUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE? *Patrizia Tosi Hematology Unit, Department of Oncology and Hematology, Infermi Hospital, Rimini, Italy *Correspondence
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationBreast Cancer. Breast Cancer Page 1
Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationA Focus on Multiple Myeloma
A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.
More informationPharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans
Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans C. Daniel Mullins, PhD Professor Pharmaceutical Health Services Research Department University
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More information